Pharmaceuticals New Zealand

New Zealand Precision Oncology Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

New Zealand Precision Oncology Market Industry Trends and Forecast to 2034: Segmented by (Product, Cancer, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

New Zealand · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $1.17 Bn Placeholder estimate
Estimate 2025 $1.28 Bn 1.1% of the global market
Projected 2034 $3.00 Bn 133.9% Adds $1.72 Bn over 9 forecast years
CAGR 2025–2034 9.9% Faster than 58% of 160 Pharmaceuticals markets here
Key players 5
  • New Zealand is 1.11% of the global market.
  • In APAC, the largest is China at $10.57 Bn.
  • Fastest growing: India at 12.8% a year.
  • New Zealand ranks 5th of 10 by size in APAC.

Market size projection

New Zealand

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.72 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Precision Oncology Market market size by year, New Zealand
YearMarket sizeChange that yearSince 2025
2024 (estimate) $1.17 Bn — —
2025 (base) $1.28 Bn +$115.4 Mn —
2026 (forecast) $1.41 Bn +$126.9 Mn +9.9%
2027 (forecast) $1.55 Bn +$139.4 Mn +20.8%
2028 (forecast) $1.70 Bn +$153.2 Mn +32.7%
2029 (forecast) $1.87 Bn +$168.4 Mn +45.9%
2030 (forecast) $2.05 Bn +$185.1 Mn +60.3%
2031 (forecast) $2.26 Bn +$203.4 Mn +76.2%
2032 (forecast) $2.48 Bn +$223.5 Mn +93.6%
2033 (forecast) $2.73 Bn +$245.7 Mn +112.8%
2034 (forecast) $3.00 Bn +$270.0 Mn +133.9%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

New Zealand Precision Oncology Market Analysis at a glance
Market size, 2025$1.28 Bn placeholder estimate
Forecast, 2034$3.00 Bn placeholder estimate
Growth (CAGR), 2025–20349.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsProduct, cancer and end user (see all)
Key playersRoche, Illumina, Inc., Tempus, Caris Life Sciences, Thermo Fisher Scientific Inc. (see all)
Regulator in New ZealandMedsafeSource: Medsafe. Checked 14 Nov 2026.
Active clinical trials2 in New ZealandSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in New Zealand. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The New Zealand Precision Oncology Market Analysis Executive Summary

Precision oncology matches cancer treatment to the genetic changes in a patient's tumour, using tests and targeted drugs.

Key segments of the precision Oncology market include product (Genomic Tests, Targeted Therapies and Informatics Platforms) and cancer (Lung, Breast and Colorectal).

Bar chart: New Zealand Precision Oncology market size, 2024–2034, placeholder estimates. $1.17 Bn in 2024, $1.28 Bn in 2025 and $3.00 Bn in 2034, 9.9% CAGR.
New Zealand Precision Oncology market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

New Zealand Precision Oncology Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the precision Oncology market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the precision Oncology market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the precision Oncology market, especially in low- and middle-income countries.

Competitive Landscape for Precision Oncology Market in New Zealand

The precision Oncology market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Precision Oncology Market in New Zealand

Precision Oncology in New Zealand: rules, payment and research

Medsafe, part of the Ministry of Health, approves medicines before they can be sold.⁠[1] Pharmac decides which medicines and medical devices the public health system pays for.⁠[2] ClinicalTrials.gov lists 2 studies on Precision Oncology that are recruiting, active or about to start in New Zealand.⁠[3]

[1] Medsafe. Checked 14 Nov 2026.

[2] Pharmac. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in New Zealand. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for precision Oncology. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in New Zealand.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Precision Oncology right now, from free public sources.

Clinical trials

2 active trials in New Zealand

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Tempus 5 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Orca Biosystems, Inc. 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Precision Oncology in context

New Zealand compared

  • Health spending per person: 5,022 US$ per person (2024). World: 1,317 US$ per person (2023). 2nd highest of the 15 countries we cover in APAC.[1]
  • Doctors: 3.61 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 2nd highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 17.6% of people (2025). World: 10.4% of people (2025). 4th highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 18 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 18 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Precision Oncology market in New Zealand?
Placeholder estimate: about $1.28 Bn in 2025, rising to about $3.00 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Precision Oncology market in New Zealand growing?
Placeholder estimate: about 9.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Precision Oncology market report cover?
The report splits the market by product (Genomic Tests, Targeted Therapies, Informatics Platforms), cancer (Lung, Breast, Colorectal, Blood Cancers) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Precision Oncology market?
Key players include Roche, Illumina, Inc., Tempus, Caris Life Sciences and Thermo Fisher Scientific Inc..
What is driving the Precision Oncology market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the precision Oncology market. Faster approvals and new combinations are improving survival.
Who regulates Precision Oncology in New Zealand?
Medsafe, part of the Ministry of Health, approves medicines before they can be sold. Source: Medsafe. Checked 14 Nov 2026.
How is healthcare paid for in New Zealand?
Pharmac decides which medicines and medical devices the public health system pays for. Source: Pharmac. Checked 14 Nov 2026.
How many clinical trials on Precision Oncology are running in New Zealand?
2 studies are recruiting, active or about to start in New Zealand, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in New Zealand. Retrieved 12 Nov 2026.
How much research is published on Precision Oncology?
PubMed lists 7,542 papers on Precision Oncology added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in New Zealand

See all

Related on oncology and genomics

See the topic